European markets have shown mixed performance recently, with the STOXX Europe 600 Index remaining relatively stable amidst fluctuating economic data and geopolitical developments. As investors navigate these uncertainties, identifying stocks that are potentially undervalued can offer opportunities for growth, particularly when they are estimated to be significantly below their intrinsic value.
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Verisure (OM:VSURE) | €8.962 | €17.71 | 49.4% |
| RaySearch Laboratories (OM:RAY B) | SEK179.60 | SEK357.98 | 49.8% |
| PSI Software (XTRA:PSAN) | €45.00 | €88.94 | 49.4% |
| Mare Group (BIT:MARE) | €5.06 | €10.02 | 49.5% |
| KB Components (OM:KBC) | SEK44.00 | SEK87.57 | 49.8% |
| Hensoldt (XTRA:HAG) | €82.70 | €165.29 | 50% |
| Endomines Finland Oyj (HLSE:PAMPALO) | €9.52 | €18.87 | 49.5% |
| CTT Systems (OM:CTT) | SEK141.00 | SEK279.71 | 49.6% |
| Borregaard (OB:BRG) | NOK155.80 | NOK309.96 | 49.7% |
| Alimak Group (OM:ALIG) | SEK127.20 | SEK252.05 | 49.5% |
Let's dive into some prime choices out of the screener.
Overview: Almirall, S.A. is a biopharmaceutical company specializing in skin health, operating across multiple regions including Spain, Europe, the Middle East, the United States, Asia, and Africa with a market cap of approximately €2.29 billion.
Operations: The company's revenue is primarily derived from its Commercial Areas, with €111.62 million from Licensees, €959.86 million from its Own Network in Europe, and €40.88 million from its Own Network in the United States.
Estimated Discount To Fair Value: 44.9%
Almirall is trading at €10.5, significantly below its estimated future cash flow value of €19.07, suggesting it may be undervalued based on cash flows. The company has forecasted earnings growth of 25.6% annually, outpacing the Spanish market's 11.5%. Recent strategic alliances in dermatology and confirmed guidance for a 9-12% sales increase further support potential value appreciation despite slower revenue growth compared to high-growth benchmarks.
Overview: Recticel SA/NV is an insulation company offering thermal and thermo-acoustic solutions across various regions including Belgium, France, the Netherlands, Germany, Slovenia, other EU countries, the UK, the US and internationally with a market cap of €735.65 million.
Operations: Recticel generates its revenue by providing insulation solutions focused on thermal and thermo-acoustic applications across multiple regions including Belgium, France, the Netherlands, Germany, Slovenia, other EU countries, the UK, and the US.
Estimated Discount To Fair Value: 32.8%
Recticel is trading at €13.04, which is 32.8% below its estimated future cash flow value of €19.41, indicating potential undervaluation based on cash flows. Despite a net loss of €15.98 million for the first half of 2026, earnings grew by 240.1% over the past year and are projected to grow significantly at 25.8% annually, exceeding Belgian market averages, although revenue growth forecasts remain modest at 8.7%.
Overview: Kempower Oyj specializes in manufacturing and selling electric vehicle charging equipment and solutions for a variety of vehicles across the Nordics, Europe, North America, and globally, with a market cap of €586.61 million.
Operations: The company's revenue from electric equipment amounts to €281.10 million.
Estimated Discount To Fair Value: 22%
Kempower Oyj, trading at €10.58, is priced 22% below its estimated future cash flow value of €13.56, suggesting undervaluation based on cash flows. The company anticipates significant improvement in 2026 operative EBIT from a previous loss of €12.4 million in 2025. Despite a net loss reduction to €1.6 million for Q2 2026 and revenue growth forecasted at 16.1% annually, the share price remains volatile amid executive changes and revised earnings guidance.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com